Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
Stock Ideas
ETF Research Tools
ETF Center
ETF Screener
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Dividends
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Portfolio
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
More...
Plans
News
Smart Portfolio
Expert Center
Ideas
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed Tools
Try Now
Stock Ideas
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETFs
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Dividends
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto
Crypto Center
Bitcoin
Ethereum
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Portfolio
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
News
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
More
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing
SRNE
The Fly
Scilex announces commercial launch of ELYXYB in the U.S.
3M ago
SCLX
SRNE
The Fly
Four new option listings and one option delisting on February 24th
3M ago
ESLT
SRNE
The Fly
Sorrento Therapeutics approved for $75M in financing in chapter 11 case
3M ago
SCLX
SRNE
Press Releases
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
4M ago
SRNE
Press Releases
Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
4M ago
SRNE
The Fly
Sorrento receives court approval for ‘First Day’ wages, cash management motions
4M ago
SRNE
Press Releases
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
4M ago
SRNE
The Fly
Scilex says not a debtor in Sorrento’s voluntary Chapter 11 filing
4M ago
SCLX
SRNE
The Fly
Sorrento Therapeutics downgraded to Neutral from Buy at Dawson James
4M ago
SRNE
The Fly
Sorrento Therapeutics files for Chapter 11 bankruptcy in Texas
4M ago
SRNE
Press Releases
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
4M ago
SRNE
The Fly
Scilex acquires rights to FDA-approved ELYXYB in U.S., Canada
4M ago
SRNE
Press Releases
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
4M ago
SRNE
Press Releases
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock
4M ago
SRNE
Press Releases
Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
4M ago
SRNE
Press Releases
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
4M ago
SRNE
The Fly
Sorrento Therapeutics price target lowered to $13 from $20 at H.C. Wainwright
4M ago
SRNE
Press Releases
Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
4M ago
SRNE
Press Releases
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
4M ago
SRNE
The Fly
Sorrento Therapeutics releases Phase 1b data of OVYDSO
5M ago
SRNE
Press Releases
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
5M ago
SRNE
The Fly
Notable open interest changes for January 6th
5M ago
AAPL
BBBY
Show More
You need to enable JavaScript to run this app.